Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q3FY25 results Total Income: Rs 527.37 crore compared to Rs 528.77 crore during Q3FY24, change -0.26%. EBITDA: Rs 50.94 crore compared to Rs 52.86 crore during Q3FY24, change -3.63%. EBITDA margin: 9.66% for Q3FY25. PAT: Rs 20.55 crore compared to Rs 23.23 crore during Q3FY24, change 11.5%. PAT margin: 3.90% for Q3FY25. Vikas Gupta, Joint Managing Director, said: “We are pleased to report our Q3FY25 Results as despite challenges such as pricing pressures, stagnant demand, and intense market competition, the company has successfully maintained stable and sustainable performance. This resilience reflects our strategic approach and adaptability in a dynamic business environment. Confident of our resilient performance, the Board has declared an interim dividend of Rs 4/- (40%) per share of face value of Rs 10 each for FY25 and fixed a Record Date for 18th February 2025 for ascertaining the entitlement. Moving forward, we remain committed to our longterm vision by focusing on market diversification and expansion to unlock new growth opportunities. Additionally, we are implementing comprehensive cost optimization measures to enhance operational efficiency, improve profitability, and reinforce our competitive position. ” Result PDF